Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • UK
  • Africa
  • Afrique
  • CH

Browsing Tag

EAACI

6 posts
NNovartis
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Read More

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

  • 2026-06-12
Novartis Pharma AG Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs…
NNovartis
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Read More

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

  • 2026-06-12
Novartis Pharma AG Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs…
NNovartis
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Read More

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

  • 2026-06-12
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable…
NNovartis
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Read More

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

  • 2026-06-09
Novartis Pharma AG Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible…
NNovartis
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Read More

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

  • 2026-06-09
Novartis Pharma AG Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible…
NNovartis
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Read More

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

  • 2026-06-08
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be…
Switzerland
www.europesays.com